Navigation Links
Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
Date:1/31/2012

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), has released upgrades to its electronic data capture system SynCapture™, providing customers with increased user functionality. SynCapture allows for clinical study data to be captured into a single database using multiple modes of entry including paper, fax, and web based, resulting in more seamless, flexible and cost effective data capture.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

"We understand that low cost EDC is critical, especially in smaller trials," said Wendel Barr, chief executive officer at Synteract. "SynCapture has been an effective solution to handle the needs of our clients since it was first implemented in 2005.  SynCapture 1.5 integrates features that enhance our cost efficient EDC offering, so we can continue to meet each client's unique program requirements."

SynCapture 1.5 provides users the ability to re-query investigative sites on data collected, an upgrade sponsors requested. In addition, the new release brings enhanced audit trail legibility and functionality useful to all project team members, as well as features that increase the ease and efficiency of the query resolution process.

"SynCapture 1.5 provides users increased functionality and easier data collection," said Olivia Montano, senior director of clinical data management at Synteract. "The main reason for the upgrade was to improve the user experience.  We took into account direct requests from users, since customer service is so integral to what we do at Synteract. This SynCapture upgrade allows us to provide clients an improved option for on-time delivery of quality data to help them get to decision points faster."

About Synteract, Inc.

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424

 


'/>"/>
SOURCE Synteract, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/19/2017)... -- South Korea Insulin Delivery Market ... "South Korea Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
(Date:1/18/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Breast Imaging Technologies Market by ... the global breast imaging technologies market size was valued at ... million by 2022, growing at a CAGR of 8.4% from ... Europe together accounted for over three-fourths ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Cosmetic Town, ... plastic surgery procedures in order to make it easier for their readers to get ... the body they impact as well as the techniques used on those particular areas. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... ... 19, 2017 , ... In 2009, Carol Bryan endured immense ... severe facial disfiguration. After four frightening years of isolation and emotional and physical ... who removed the substances in a partial facial transplant through eight surgeries. ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Sam ... planning assistance to commercial and residential clients in the California Bay Area, is launching ... heart health in the region. , Heart disease is the primary killer of adult ...
Breaking Medicine News(10 mins):